- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03977597
Evaluation of Diaphragmatic Function After Bi-pulmonary Transplantation (DIATRIB)
A current complication after lung transplantation is diaphragmatic dysfunction. These dysfunction result to several factors: duration of mechanical ventilation, chest tube, atelectasis, denutrition, phrenic nerve injury during surgical dissection… Only monocentric and retrospective studies collected diaphragmatic paralysis after lung transplant are published. The incidence of diaphragmatic paralysis in post-operative lung transplantation varies from 3.2% to 16.8%.
The main hypothesis of the study is to defined the incidence of diaphragmatic dysfunction in post-operative lung transplantation.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Thibaut GENTY, MD
- Phone Number: 0140942260
- Email: t.genty@hml.fr
Study Locations
-
-
-
Le Plessis-Robinson, France, 92350
- Recruiting
- Centre Chirurgical Marie Lannelongue
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults (≥ 18 years old)
- Admitted for intensive care that can be spontaneously ventilated after bi- pulmonary transplantation
Exclusion Criteria:
- Minor patient
- Ventilated patients less than 24 hours
- patients in controlled ventilation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence of diaphragmatic disorders (paralysis, severe and moderate dysfunction) in the post-operative period of bi-pulmonary transplantation
Time Frame: 21 days
|
incidence of diaphragmatic disorders (paralysis, severe and moderate dysfunction) in the post-operative period of bi-pulmonary transplantation
|
21 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2018-A02418-47
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Transplant, Diaphragmatic Function
-
University of ManitobaCompletedLung Function | Diaphragmatic FunctionCanada
-
Guy's and St Thomas' NHS Foundation TrustAstellas Pharma Europe Ltd.Unknown
-
Stanford UniversityCompletedFunction of Renal TransplantUnited States
-
Nantes University HospitalTerminated
-
University Hospital Schleswig-HolsteinUniversity of KielCompletedFunction of Renal TransplantGermany
-
Ha Young OhBaxter Healthcare CorporationUnknownAcute Rejection of Renal Transplant | Delayed Function of Renal Transplant | Primary Nonfunction of Renal TransplantKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterTerminatedHematopoietic Stem Cell Transplant | Poor Marrow Graft FunctionUnited States
-
King Chulalongkorn Memorial HospitalRecruitingKidney Transplant; Complications | Delayed Graft Function | Kidney FunctionThailand
-
Schroppel, Bernd, M.D.Alexion PharmaceuticalsTerminatedDelayed Function of Renal TransplantUnited States
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation; Cooperative Clinical Trials in Pediatric...CompletedKidney Transplant | Kidney Transplant Recipient | Graft Function/Survival | de Novo HLA Antibodies DevelopmentUnited States